Latent transforming growth factor binding protein 4 (LTBP4) is downregulated in mouse and human DCIS and mammary carcinomas by Kretschmer, C. et al.
ORIGINAL PAPER
Latent transforming growth factor binding protein 4 (LTBP4)
is downregulated in mouse and human DCIS and mammary
carcinomas
Celine Kretschmer & Anne Conradi &
Wolfgang Kemmner & Anja Sterner-Kock
Accepted: 13 March 2011 /Published online: 6 April 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract
Background Transforming growth factor beta (TGF-ß) is able
to inhibit the proliferation of epithelial cells and is involved in
the carcinogenesis of mammary tumors. Three latent trans-
forming growth factor-ß binding proteins (LTBPs) are known
to modulate TGF-ß functions.
Methods The current study analyses the expression profiles
of LTBP4, its isoforms LTBP1 and LTBP3, and TGF-ß1,
TGF-ß2, TGF-ß3, and SMAD2, SMAD3 and SMAD4 in
human and murine (WAP-TNP8) DCIS compared to invasive
mammary tumors. Additionally mammary malignant (MCF7,
Hs578T, MDA-MB361) and non malignant cell lines
(Hs578BsT) were analysed. Microarray, q-PCR, immu-
noblot, immunohistochemistry and immunofluorescence
were used.
Results In comparison to non-malignant tissues (n=5),
LTBP4 was downregulated in all human and mouse DCIS
(n=9) and invasive mammary adenocarcinomas (n=5) that
were investigated. We also found decreased expression of
bone morphogenic protein 4 (BMP4) and increased expression
of its inhibitor gremlin (GREM1). Treatment of the mammary
tumor cell line (Hs578T) with recombinant TGF-ß1 rescued
BMP4 and GREM1 expression.
Conclusion We conclude that the lack of LTBP4-mediated
targeting in malignant mammary tumor tissues may lead to
a possible modification of TGF-ß1 and BMP bioavailability
and function.
Keywords LTBP4 . TGF-ß . DCIS .Mammary carcinoma .
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1 Introduction
The rising use of screening mammography starting in the
early 1980s resulted in an increase in detection of the ductal
carcinoma in situ (DCIS) and invasive ductular carcinomas
(IDCs) especially among women over 50 years of age [29].
DCIS represents 20–45% of all new cases of mammo-
graphically detected breast cancer, and about 10% of all
breast carcinomas [46]. Improving diagnosis and treatments
for patients will likely depend on finding unique molecular
markers or other features that distinguish different types
and stages of tumors from each other and from non-
malignant tissue.
Modern microarray technologies for gene expression
profiling can provide such insights into the molecular
features of DCIS and IDCs. Relatively few such studies of
these tissues have been carried out to date and most focus
on the identification of genes associated with tumor
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progression, by comparing in situ and invasive neoplasias
[33, 41, 48]. One bottleneck has been the limited number of
samples of mammary neoplasms, including DCIS, that are
available. To overcome this problem in our study, an
additional transgenic mouse model for DCIS was used [49].
The mice are transgenic for the WAP-SV40 early genome
region, so the expression of the SV40 oncogene is activated
by lactation. The use of these transgenic animals offers the
possibility of identifying tumor-initiating factors and
investigating gene expression profiles at different stages
of tumor development.
Transforming growth factor-ßs (TGF-ßs) have a wide
range of functions and have been implicated in many
types of cancer [24]. TGF-ßs belong to a large superfamily
of secreted polypeptides which modulate growth and
differentiation in multiple cell types and control the
homeostasis of extracellular proteolysis. They play impor-
tant roles during many stages of development. The
putative tumor suppressor gene TGF-ß1 is able to inhibit
epithelial proliferation [17] and is involved in the
carcinogenesis of human mammary tumors [9, 18–20, 23,
30, 52, 56].
During development and in multiple pathological pro-
cesses, the activity of all TGF-ß superfamily members is
strictly regulated through association with other molecules.
After secretion, TGF-ßs initially remain biologically latent.
In its mature form, the molecule forms dimers that are kept
inactive by an amino-terminal propeptide (LAP). Although
this peptide is cleaved during the secretion of TGF-ß, it
remains associated with the molecule by non-covalent
interactions. The activation of TGF-ß requires its dissoci-
ation from LAP [54].
In most cell types TGF-ß is secreted in a latent form
associated with latent TGF-ß binding protein (LTBP) [37].
In combination, the molecules may be targeted to specific
extracellular structures, providing the main means by which
the spatial and temporal activity of TGF-ß is controlled.
TGF-ß accumulates in the microfibrillar ECM structures in
its latent form. TGF-ß extracellular matrix secretion,
deposition and latency are strictly linked to their binding
proteins (LTBPs).
Currently four different LTBPs have been cloned from
mammals (LTBP1 to LTBP 4). LTBP1, LTBP 3 and LTBP4
bind covalently to TGF-ß1-LAP [13, 39, 53, 57, 61].
LTBPs are released from the extracellular matrix (ECM) by
various proteinases including plasmin [16].
There is evidence that changes in TGF-ß expression
levels, signaling, and possibly other aspects of its behavior
are linked to the activation of the BMP pathway. Aberrant
expression patterns of BMP, which have been correlated to
outcomes and prognosis in breast cancer, as well as stages
of tumor progression [60], might be correlated to changes
in TGF-ß signaling. Since TGF-ß function is determined by
its association with LTBPs, it is not surprising to find
changes in LTBP4 expression in the malignant transforma-
tion of the investigated tumors. This, in turn, might provide
a link between BMP and changes in LTBP4 expression
levels [27, 35].
LTBPs are needed for the secretion and folding of TGF-ß
[8, 21, 37]; they have also been proposed to play an
important role in the pathogenesis of mammary neoplasms.
Some epithelial carcinomas showed lower LTBP1 and
LTBP3 expression compared to non-malignant tissue taken
from the same individual [7, 28, 42]. LTBP1 is down-
regulated in a variety of human epithelial neoplasms of the
liver [45], ovaries [15] and in neuroendocrine tumors of the
digestive system [6]. Dysregulated expression of LTBP
isoforms seem to be related to the onset of epithelial
neoplasms.
Here we investigated the possibility that changes in
LTBP4 expression might be linked to the carcinogenesis of
human mammary carcinomas, DCIS as well as mouse
mammary tumors and DCIS. We discovered that LTBP4 is
consistently downregulated in human and mouse DCIS and
mammary tumors compared to primary (non-transformed)
mammary epithelial cells. This suggests that the gene may
be involved in neoplastic transformation of human mam-
mary tumors and could play a role as a putative tumor
suppressor gene.
2 Material and methods
2.1 Mice
WAP-TNP8 animals, which selectively synthesize the T/t-
antigen under the control of the WAP (whey acidic protein)
promoter in the mammary gland epithelial cells, were used
for this study [49]. The WAP promoter is hormonally and
developmentally regulated by lactotrophic hormones. Thus
expression of the SV40 large tumor antigen can be induced
by mating and is directed to epithelial cells of the
differentiating and lactating glands ([49]). Females were
allowed to nurse their offspring for 3 to 4 weeks. Wild type
mice (non-transgenic) and transgenic mice before lactation
were used as negative controls and were combined as non-
malignant control samples. Mice were analysed 2 months
after lactation (abbreviated as 2 M), 3 months after lactation
(3 M), 4 months after lactation (4 M) and 5 months after
lactation (5 M). In this way we were able to study the
different time points of the development of DCIS. Also a
group of invasive ductal carcinomas (IDC) was investigated
in the similar way and served as positive control. For
subsequent analysis, mice were sacrificed and mammary
420 C. Kretschmer et al.
glands were dissected. Tissue samples of mouse mammary
glands were cut in unbiased, random, isometric planes of
sections (according to Cavalieri princile) and histopatho-
logically evaluated. The investigated WAP-TNP8 mice
mainly developed DCIS 5 to 6 months after lactation. But
already 2 to 3 months after lactation around 30% of the
mice showed DCIS. After morphological evaluation and
diagnosis predominantly high grade DCIS were identified.
Tissue sections for RNA isolation were snap-frozen in
liquid nitrogen and stored at −80°C.
For the Affymetrix gene expression analysis five
samples per group (in total 40 Microarrays) were analyzed.
For the subsequent quantitative real time PCR the groups
were enlarged at seven mice per group.
2.2 Human tissue
Nineteen fresh-frozen human breast samples (non-malignant,
DCIS and IDC) were obtained from the Robert-Rössle-
Biobank at the ECRC (Experimental and Clinical Research
Center). Tissue samples were cryopreserved immediately
after surgery in liquid nitrogen and stored at −80°C. All
participants gave written, informed consent. The patient
cohort consisted of nine DCIS, five invasive ductal
carcinoma (IDC) and five non-malignant control samples
obtained from patients with breast reduction surgery. All
samples were reviewed for histological classification
according to nuclear grade. The human samples were
tumor grade 2 and 3 (6 DCIS & 3 IDC grade 3, 3 DCIS
& 2 IDC grade 2). Average age of the human patients
was 63 years. They were all free of distant metastasis.
For the human gene expression analysis (Microarray and
TaqMan) the patient cohort consisted of nine DCIS, five
invasive ductal carcinoma (IDC) and five healthy control
samples. A second panel consisting of human formalin-fixed
paraffin-embedded (FFPE) tissue samples was used for
immunohistochemical staining.
2.3 Cell culture
Human breast cancer MCF-7 and MDA-MB-361 (ATCC,
USA) cells were cultured in DMEM (ATCC, USA)
supplemented with 10% fetal calf serum (Invitrogen,
Karlsruhe Germany), 1% sodiumpyruvate 100 mM (Invi-
trogen, Karlsruhe Germany), 1% Glutamin 200 mM
(Invitrogen, Karlsruhe Germany), 1% 10.000 U/ml penicillin/
10.000μg/ml streptomycin (Invitrogen, Karlsruhe Germany) at
37°C and 5% CO2 in flasks.
Hs578T tumor cells (ATCC, USA) were cultured in
DMEM (ATCC, USA) supplemented with 10% fetal calf
serum, 2% 10.000 U/ml penicillin/10.000 μg/ml strepto-
mycin, 0,2 ml/500 ml bovine Insulin (Roche, Mannheim
Germany) at the same conditions. The matched non tumor
cell line Hs578Bst (ATCC, USA) was maintained in
Hybri-care Culture-Medium (ATCC, USA) supplemented
with 10% fetal calf serum, 2% 10.000 U/ml penicillin/
10.000 μg/ml streptomycin and 30 ng/ml Epidermal
Growth Factor (Invitrogen, Karlsruhe Germany) at 37°C
and 5% CO2. Upon reaching approximately 85% conflu-
ence, cells were detached with 0,05% trypsin and 0,02%
EDTA in PBS, sub cultured in new flasks and used for the
assays.
It has been shown in the literature that the chosen cell
lines MCF-7, Hs578T and Hs578BsT are sensitive to TGF-ß
signaling and are therefore widely used to investigate the
TGF-ß/BMP pathway [12, 31, 34, 55].
Conditioned medium was prepared by a 3 to 24 h
incubation of the Hs578T or Hs578BsT cells. The medium
of the receiving cell population was removed, cells were
washed and then incubated with conditioned media or
medium containing recombinant TGF-ß in concentrations of
(0.2 to >30 pM) to 1,6×105 cells.
For rescue experiments Hs578T cells were used. Re-
combinant TGF-ß1 (0.2 to >30 pM) was added to cells and
incubated for 24 h. BMP4 and gremlin expression was
monitored by immunoblot.
2.4 RNA isolation and RT-PCR
Murine total cellular RNA and total cellular RNA of cell
culture cells was isolated using the RNeasy Mini Kit
(Qiagen, Hilden Germany) with on column DNAse I
(Qiagen, Hilden Germany) digestion according to manu-
factures instructions including a DNAse digestion step.
Human total RNA was isolated with RNeasy Lipid Tissue
Mini Kit (Qiagen). On the one hand, RNA concentrations
and purities were determined spectrophotometrically using a
Bio Photometer (Eppendorf, Hamburg Germany) or Nano-
Drop® ND-1000 (Thermo Scientific, Dreieich). A260/A280
ratios were calculated for evaluation of protein impurities.
The A260/A280 ratio was 1.8–2.2, suggesting that the
isolated RNA was free of protein. On the other hand,
RNA concentrations and purities were determined using
Agilent 2100 Bioanalyzer (Agilent Technologies, Böblingen,
Germany). RIN (RNA integrity number) of the used
RNA samples was always about 6,7. RNA yield was
between 130,3 ng/μl and 189,0 ng/μl for the human
samples and 2,5 ng/μl and 31,7 ng/μl for the murine
samples.
Quantitative PCR was performed using TaqMan® Gene
Expression Assays and the ABI Prism™ 7900 HT
Sequence Detection System (Applied Biosystems, Foster
City, CA, USA). Gene Expression Assay IDs are listed in
Table 1. For the mice samples RNA UltraSense™ One-Step
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Quantitative RT-PCR System (Invitrogen, Karlsruhe
Germany) was used. Procedure was performed in accor-
dance to the manufacturer’s guide. For human RNA, cDNA
synthesis was done using 1 μg total RNA, Oligo(dT)
primers (500 μg/ml) (Biotez, Berlin, Germany) and
SuperScript II (200 U/μl) (Invitrogen, Karlsruhe Germany)
according to the protocol of Invitrogen. qPCR for the
human cDNAwas performed using the TaqMan® Universal
PCR Master Mix (Applied Biosystems, Foster City, CA,
USA). For cell culture samples only a reverse transcription
PCR was performed, therefore reverse transcription (RT)
was performed using RT-buffer (Roche, Mannheim
Germany), Expand Reverse Transcriptase, 50U/μl (Roche,
Mannheim Germany), dNTP-Mix, 2 mM (MBI Fermentas,
St. Leon-Roth Germany), Oligo(dT) Primer (Promega,
Mannheim Germany), DTT (MBI Fermentas, St. Leon-
Roth Germany) and RNasin RNAse Inhibitor, 40U/μl
(Promega, Mannheim Germany). PCR primers (Table 1)
were designed to amplify the cDNA. Sequence information
was obtained from GenBank accession number
NM_003573. PCR reaction was performed using the
Taq-polymerase system (Qiagen, Hilden Germany)
according to the manufactures’ instructions and basic
protocols. For cloning, overhanging adenosine nucleotides
were added using a terminal adenosyl-transferase (A-Addition-
Kit, Qiagen, Hilden Germany). Generally, cDNAwas stored
at −20°C.
For relative quantification of gene expression, triplicate
reactions were set up. Expression of ß-actin served as
reference gene because ß-actin expression levels were
consistent throughout all samples in the cDNA microarray
data. H2O wells (NTC = no-template controls) were used as
a negative control. Reactions were performed in 384 well
format using 10 μl total volume per well and a minimum of
12 ng RNA or cDNA per well. PCR products were checked
by agarose gel electrophoresis.
The relative expression of the LTBP4 in the quantita-
tive real time PCR was calculated according to the ΔΔCt
method [32] using an internal reference sample as
calibrator.
2.5 Affymetrix GeneChip analysis
Two-round linear amplification, using 50 ng total RNA,
was carried out for the murine samples according to
GeneChip® Two-Cycle Target Labelling protocol (Affyme-
trix). In human samples cRNA was amplified from 1 μg of
total RNA using GeneChip® One-Cycle Target Labelling
Kit (Affymetrix). The quantity of in vitro transcription and
fragmentation products was assessed using the Agilent
2100 Bioanalyzer. Labelled and fragmented cRNA was
hybridized for 16 h at 45°C on Affymetrix oligonucleotide
Murine Genome 430 2.0 or Human Genome U133 plus 2.0
Arrays. Hybridized arrays were scanned using GeneChip
Scanner 3000. Linearized raw expression values were
extracted. An initial analysis of the murine and mouse
microarrays was performed using the Affymetrix Micro-
array Suite 5.0 (MAS5) software. The percentage of
present calls, background noise, the scaling factor, and
the ratio of 3′ to 5′ hybridization for GAPDH and ß-actin
were used to assess quality of hybridization. Raw image
data were converted to CEL files using the Affymetrix
GeneChip Operating Software (GCOS). For adjacent
analyses of microarray data, the GeneSpring GX 10.0
Software (Agilent Technologies) was used. GCRMA (GC
robust multiarray average) was used to perform back-
ground correction and normalization. Focus of the
analysis was set on the modified expression of LTBP4
and related genes in malignant samples compared to non-
malignant samples.
The relative expression values for each gene are shown
as Box and Whisker Plots. Median of the values of each
group is marked with a line within the box. The box
extends from the 25th to the 75th percentile. The whiskers
extend down to the lowest value and up to the highest. The
mouse data is deposited as GEO series GSE21444, and the
human as GSE21422.
2.6 Haematoxylin-Eosin stain and immunohistochemistry
Tissue was fixed in Zink-Formalin Fix Concentrate
(Thermo Shandon, USA). Tissue sections were stained
using standard histology procedure according to the
method described by Romeis with Haematoxylin and Eosin
[44].
For immunohistochemistry the cells were incubated with
the primary antibody in Dulbecco’s PBS for 1 h at room
temperature.
Rabbit antibodies against human LTBP4 (concentration
200 μg/ml, dilution 1:100) and p-SMAD, total SMAD2
Gene Assay-on-Demand ID/Sequence
Murine RT-PCR assays LTBP4 Mm00723639_g1
Human RT-PCR assays LTBP4 Hs00186025_m1
LTBP4 b forward 5′-GAC GGC TAC TCA GAT GCCTC-3′
LTBP4 b reverse 5′-GCC TCT GAG ATC ACG TGT TGG-3′
Table 1 Assays on demand
(Applied Biosystems) and PCR
Primer sequences used for the
RT-PCR
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and SMAD3 (concentration 200 μg/ml, dilution 1:200)
were obtained from Santa Cruz Biotechnology (Heidelberg
Germany). The binding of the antibodies was detected
using AP-conjugated secondary antibodies in the Fuchsin
Substrate-Chromogen System (DakoCytomation, Hamburg
Germany). The tissue sections were finally washed in
TBS, treated with anti-fading reagent Glyceringelatine
(Merck, Darmstadt Germany), and examined under the
microscope (Zeiss IM 35, Göttingen Germany) using a
40× objective.
2.7 Immunoblot
Equal numbers of cells of all three cell lines were
homogenized in cell-lysis-buffer (150 mM NaCl, 0,1%
NP-40, 10% Glycerol, 25 mM Natrium-ß-Glycerophosphat
in 50 mM Tris–HCl at pH 7.4). After centrifugation and
adding protease inhibitors (Roche, Mannheim Germany)
the supernatants were used for immunoblotting.
Equal amounts of protein (100 μg/ml) were determined
using BCA Protein Assay Kit (Pierce, USA) and applied for
immunoblot reaction.
SDS-PAGE was performed according to standard proto-
cols using 12% SDS gels (Bio-Rad Laboratories, München
Germany). Immunoblots were performed at 500 V, 196 mA,
45 min, using nitrocellulose membranes (Schleicher and
Schuell, Dassel Germany). Electrophoretically separated
proteins were transferred to nitrocellulose membranes
using semidry blotting systems (Bio-Rad Laboratories,
München Germany). Immunodetection was performed
using BMP4, p-SMAD, SMAD2, SMAD3 antibodies
(concentration 200 μg/ml, dilution 1:100) (Santa Cruz,
Heidelberg Germany), AP-conjugated secondary antibody
(concentration 0,42 g/l, dilution 1:500) (DakoCytoma-
tion, Hamburg Germany) followed by colour reaction
BCIP/NBT (Zymed, Berlin Germany) or ECL Western
Chemiluminescent HRP Substrate (Thermo Fisher Scien-
tific, Pittsburgh USA). Recombinant BMP4 was used as
a positive control (Fig. 4). Anti-ß-actin (Sigma) was used
routinely as loading control.
3 Results
3.1 Expression of LTBP4
Analysis of LTBP4 in murine and human samples showed a
significant reduction of mRNA expression in DCIS and
invasive breast carcinoma compared to non-malignant
control samples (Fig. 1a, b). In the WAP-TNP8 mice
model, expression of LTBP4 was significantly reduced
2 months after activation of the SV 40 oncogene (Fig. 1a).
In human samples the expression of LTBP4 was signifi-
cantly reduced in both DCIS and IDC compared to non-
malignant control samples (Table 2, Fig. 1b). The findings
were validated by quantitative RT-PCR in both species
(Fig. 1a, b). P-values and Fold Changes of LTBP4 in the
groups that were investigated are provided in Table 2. We
also investigated the expression of LTBP4 in various
mammary cell lines (Fig. 1c). We could show that human
malignant mammary cell lines such as MDA-MB-361,
MCF7 and Hs578T revealed almost complete downregula-
tion of LTBP4. This was in sharp contrast to the non-
transformed mammary cell line Hs578BsT (matched cell
line to Hs578T), which showed LTBP4 expression at levels
comparable to those of non-malignant human breast tissue
(Fig. 1c).
3.2 Immunohistochemistry of LTBP4 in human
non-malignant ductular epithelial cells, DCIS and IDC
Non-malignant ductular epithelial cells revealed a clear
LTBP4 signal in ductular epithelial cells (Fig. 1d). There
was no signal present in DCIS (Fig. 1d2, d3) or invasive
carcinomas.
3.3 Expression of TGF-ß and LTBP isoforms
Conceivably, the downregulation of LTBP4 might inter-
fere with TGF-ß transcription or change the balance of
its three isoforms. To exclude this, we compared the
transcription of TGF-ß1, TGF-ß2 and TGF-ß3 in IDCs to
non-malignant breast tissue (Fig. 2c–e) using gene arrays
and found no significant differences. Another question
was whether the downregulation of LTBP4 downregula-
tion might lead to the compensatory upregulation of the
LTBP isoforms LTBP1 and LTBP3. These isoforms are of
interest because they are the forms that bind to TGF-ß1.
Changes in their expression levels might change patterns
of TGF-ß secretion, and that might influence the signaling
pathways that it normally activates in cells that receive the
signal. But our results indicate that expression levels of
LTBP1 and LTPB3 are unaffected (Fig. 2a, b), which
means that cells do not produce more of the other isoforms
of LTBP to compensate for lower levels of LTBP4 in
DCIS and IDCs. This suggests that the isoforms are
regulated independently, suggesting that each has individ-
ual functions in epithelial cells.
3.4 SMAD expression and p-SMAD formation
Reduced LTBP4 expression could result in impaired
TGF-ß signaling. Therefore, we examined the transcrip-
tional expression of SMAD2, SMAD3 and SMAD4,
elements of the pathway. We found that the transcriptional
expression of SMAD2, SMAD3 and SMAD4 in non-
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malignant mammary tissue was similar to that in DCIS and
IDCs (Fig. 3a–c).
Our next step was to determine how a reduction in levels
of LTBP4 expression in DCIS and IDCs affects its binding
partner TGF-ß. It might result in reduced secretion of TGF-
ß, making it unavailable, or influencing its activation. To
study these possible effects we established cell cultures of
the mammary carcinoma cell line Hs578T and the matched
non-transformed cell line Hs578BsT. The tumor cell line
showed highly downregulation of LTBP4 expression
compared to the non-malignant mammary cell line
Hs578BsT (Fig. 1c).
TGF-ß signals are received by the TGF-ß receptor,
which becomes activated and phosphorylates SMAD2 and
SMAD3. They form a complex with SMAD4 that relocates
into the nucleus and form a transcription complex with
TGF-ß responsive genes. p-SMAD formation, therefore,
can be used as a monitor for TGF-ß signaling within tissues
Fig. 1 Expression analysis of
LTBP4 in murine and human
samples. a Expression of LTBP4
in WAP-TNP8 mice. Left
diagram shows the linearized
raw expression values of the
Affymetrix Mouse Genome
430 2.0 GeneChip® analysis;
right diagram shows relative
expression values of the
quantitative RT-PCR. LTBP4
is significantly downregulated
in the malignant tissues.
b Expression of LTBP4 in
human mammary tissue. Left
diagram shows the linearized
raw expression values of the
Affymetrix Human Genome
U133 Plus 2.0 GeneChip®
analysis; right diagram shows
relative expression values of the
quantitative RT-PCR. LTBP4 is
significantly downregulated in
the malignant tissues. c RT-PCR
results revealed no expression
of LTBP4 in the mammary
carcinoma a cell lines MDA-
MB-361, Hs578T and MCF7
compared to the non-malignant
mammary epithelial cell line
Hs578BsT. D: LTBP4 immuno-
histochemical staining of
human tissue samples. d1
shows positive staining in
non-malignant breast tissue
(ductus) (arrows), d2 shows
no staining in DCIS, D3 shows
no staining in invasive breast
carcinomas. Scale bar marks
20 μm
424 C. Kretschmer et al.
and cells. We examined the formation of p-smad in cell
culture and in mammary non-malignant tissues and mam-
mary tumors. We found that a striking reduction in p-
SMAD staining in Hs578T and Hs578BsT cells (Fig. 3e1,
d5) when incubated with cell conditioned media harvested
after 24 h from Hs578T (Fig. 3d, e). Upon receptor
stimulation pSMAD cytoplasmic-nuclear shuttling was
induced and was mainly evident within the nucleus,
dependent on kinetic considerations [47].
This indicates that the lack of LTBP4 leads to a reduction in
active TGF-ß1, and therefore reduced bioavailability and p-
SMAD formation. In accordance with this findings, the
addition of rTGF-ß1 to Hs578BsT and Hs578T results in the
increased formation of p-SMAD (Fig. 3d). The p-SMAD
signal could be neutralized again with the addition of
neutralizing TGF-ß antibody (data not shown).
Immunohistochemical staining of p-SMAD2/3 showing
non-malignant breast tissue with prominent p-SMAD expres-
sion and almost complete loss of immunoreactive p-SMAD
signal in mammary tumor tissue (Fig. 3f). Total SMAD2/3 in
non-malignant breast tissue and in mammary tumor tissue
did not show any differences in immunoreactivity. These
results indicate a reduced phosphorylation of SMAD2/3 in
mammary tumor tissues.
TGF-ß acts as a suppressor of cell division and a
repressor of the transcription factor c-Myc [59], suggesting
another potential link between TGF-ß activity and cancer.
The changes of TGF-ß expression seen in the tumors might
have their physiological effects by altering the behavior of
c-Myc and its target genes. Therefore, we measured
c-Myc expression in malignant mammary tissues and in
non-malignant mammary tissues. c-Myc levels were
enhanced in Hs578T cells and in mammary tumors
compared to non-malignant mammary tissues (data not
shown), another indication that TGF-ß1 signaling is
reduced in Hs578T.
3.5 Expression of BMP4, Gremlin, ID1, and ID2 in IDC
and DCIS
The connection between TGF-ß and BMP signaling
prompted us to compare the expression of bone
morphogenic protein 4 (BMP4) in DCIS and IDCs and
non-malignant mammary tissue. The microarray analysis
revealed that BMP4 expression was lower in DCIS and
IDCs than in non-malignant human and murine mam-
mary tissue (Fig. 4a, Table 3). In parallel an increase in
the expression of the BMP4 inhibitor gremlin was
observed (Fig. 5c, Table 4). There was also a significant
decrease in expression levels of the BMP4 target gene ID1
(Fig. 5a).
3.6 Modulation of the BMP pathway
For in vitro analysis the human mammary carcinoma cell
line Hs578T and the matched non-malignant cell line
Table 2 Down regulation of LTBP4 in malignant tissues
Group p-value Fold change
Microarray Murine DCIS and IDC compared
to non-malignant control
2 m 1.7E-02 2.1 ↓
3 m 4.1E-03 2.1 ↓
4 m 5.0E-03 2.0 ↓
5 m 3.5E-03 2.5 ↓
IDC 9.5E-04 11.7 ↓
Human DCIS and IDC compared
to non-malignant control
DCIS 1.8E-02 5.9 ↓
IDC 1.5E-02 8.9 ↓
qPCR Murine DCIS and IDC compared
to non-malignant control
2 m 5.5E-03 2.1 ↓
3 m 4.9E-03 2.2 ↓
4 m 1.7E-02 1.6 ↓
5 m 3.5E-03 2.4 ↓
IDC 5.6E-04 13.4 ↓
Human DCIS and IDC compared
to non-malignant control
DCIS 1.3E-02 5.7 ↓
IDC 1.0E-02 9.0 ↓
p-values and Fold Changes of LTBP4 in murine and human DCIS and IDC. p-values and fold Changes of LTBP4 in murine and human DCIS and
IDC compared to non-malignant control samples (2 m=2 month after lactation, 3 m=3 month after lactation, 4 m=4 month after lactation, 5 m=
5 month after lactation, IDC=invasive ductal carcinoma). Fold Changes were calculated using the median of the non-malignant controls compared
to the different time points or the invasive tumors. Malignant and premalignant tissues were down regulated compared to non-malignant controls.
Microarray and quantivative real time PCR values are shown
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Hs578BsT were used. The carcinoma cell line showed
clearly reduced protein levels of BMP4 (Fig. 4b).
Addition of recombinant BMP4 to Hs578T cell lines
rescued the BMP inhibitor gremlin and ID1 expression
levels, making them comparable to levels in the untrans-
formed cell line Hs578BsT (data not shown).
Fig. 2 Expression values of
LTBP1 (a), LTBP3 (b), TGFB1
(c), TGFB2 (d) & TGFB3 (e) in
murine and human samples. Left
panel shows the expression in
WAP-TNP8 mice. The right
panel shows the expression in
human mammary tissue.
Diagrams show the linearized
raw expression values of the
Affymetrix Mouse Genome 430
2.0 GeneChip®/Affymetrix
Human Genome U133 Plus 2.0
GeneChip® as Box and Whisker
Plots. No significant changes in
the expression profile were
identified
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3.7 Rescue of BMP4 and Gremlin signaling
To evaluate the relationship between these changes we
analysed whether restoring TGF-ß1 activity and signaling in
Hs578Tcells would restore BMP4 and gremlin to the levels of
expression seen in non-malignant mammary tissue (Fig. 4c).
To restore BMP4 activity in Hs578T, which does not
express LTBP4, we cultured Hs578T cells in the presence
of low-concentration TGF-ß1 (0,5 ng/ml) in normal serum
containing medium. The expression levels of BMP4 and
gremlin resembled those of non-malignant mammary tissue
(Fig. 4c).
Our in vivo findings show a correlation between TGF-ß
bioavailability and reduced expression of BMP4. Further-
more, the results indicate that BMP4 signaling is signifi-
cantly modified in mammary neoplasms, resulting in the
dysregulation of the BMP4 target genes Gremlin1 and ID1
and ID2.
4 Discussion
The present study investigated the possible role of TGF-ß
binding protein 4 (LTBP4) and TGF-ß in human DCIS and
mammary tumors and in mouse mammary carcinomas and
DCIS. To date, little is known about the interdependency of
human DCIS and invasive mammary carcinomas and the
expression of TGF-ß and its binding protein LTBP4.
What has been established so far is that all of the four
TGF-ß binding proteins identified to date (LTBP1 to
LTBP4) play an essential role in the secretion and
activation of TGF-ß [36, 54]. It has also been shown that
LTBP4 knock out mice developed epithelial carcinomas,
indicating that LTBP4 is involved in the pathogenesis of
epithelial tumors [51]. The current study investigated the
expression profiles of LTBP4 and TGF-ß1 in human and
mouse invasive mammary tumors and DCIS in a quantita-
tive manner. Furthermore downstream effects of TGF-ß
signaling were monitored.
Here we have demonstrated that LTBP4 is downregu-
lated in human and murine mammary tumors (which were
classified as adenocarcinomas according to WHO) and
DCIS in comparison to control tissue of an identical genetic
background. This downregulation is clearly associated with
tumor cells; our experiments suggest that it is functionally
important and provide a potential model for understanding
its effects on signaling pathways, particular target genes,
and tumorogenesis.
Once the process of cancer is underway, however, other
mechanisms appear to step in to guide a tumor’s develop-
ment. We did not find further changes in LTBP4 expression
that could be linked to the specific tumor type, its growth,
or its metastatic potential.
These findings are supported by Mauel et al., who
demonstrated a marked decrease in LTBP4 mRNA expres-
sion in the two mammary carcinoma cell lines (MCF-7 and
Hs578T) compared to the non-malignant matched control
cell line Hs578BsT [34].
Molecules such as LTBP4 help regulate aspects of the
TGF-ß signaling pathway by binding to TGF-ß1-LAP and
influencing its localization and activation. To document a
possible correlation between LTBP4 and TGF-ß1, we
analysed the expression of TGF-ß1. In DCIS and invasive
carcinomas (human and mouse) the results showed no
change in the expression of TGF-ß1. Also Mauel et al.
analysed TGF-ß1 and TGF-ß2 expression in human
mammary carcinoma cell lines (MCF-7, Hs578T) compared
to matched control cells (Hs578BsT). They found no
upregulation of TGF-ß1 or TGF-ß2 in the human mammary
carcinoma cell lines [34].
Others have proposed that an increased expression of
TGF-ß2 could be a possible compensatory mechanism in
response to the lack of TGF-ß1 [27]. Koli et al. describe
that the downregulation of LTBP4 in the lung tissue of mice
leads to a reduction of the activity of TGF-ß1 and no
increase in the expression of TGF-ß2 and TGF-ß3, which
agrees with the present results [25, 26].
Bascom and colleagues [1, 2] stated that TGF-ß1 is a
potent repressor of TGF-ß2 and TGF-ß3. The regulatory
mechanisms that are responsible for the expression of
TGF-ß1, TGF-ß2 and TGF-ß3 and their crosstalk are
mostly unknown [1]. It is also not known whether this
phenomenon is cell-type specific. However, it is known
that the reduced expression of TGF-ß1 would have a pro-
proliferative effect on epithelial cells, which could be a
potential inducer of a pro-carcinogenic process in epithe-
lial cells.
It is not clear whether LTBP4 downregulation results in
transformation of epithelial cells and potential neoplasia, or
if this downregulation follows upon the cells’ transforma-
tion. Koli et al. described a markedly reduced transcription
rate for LTBP1, LTBP2, LTBP3 and LTBP4 transcription
rate in SV40-transformed human embryonic lung fibro-
blasts [25, 26]. Therefore, it seems that malignant transfor-
mation of an epithelial cell type results in reduced LTBP
expression that is not necessarily LTBP-isoform specific
[26]. The fact that the transformed cell lines BA 13 and AT
1080 exhibited reduced LTBP4 expression compared to the
non-transformed cell line WI 38 provides further support
for the idea that malignant transformation is correlated to
reduced LTBP expression [28, 54]. This observation was
supported by Henriksen and colleagues, who found reduced
LTBP1 expression in human ovarian carcinomas compared
to non-malignant matched control tissue [15]. Furthermore,
the expression of TGF-ß binding proteins LTBP1 and
LTBP3 is decreased in epithelial tumors [7, 28, 42]. The
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downregulation of LTBP isoforms seems to be associated
with the formation of epithelial neoplasms.
It has been postulated that reduced LTBP expression in
malignant tumors leads to a diminished secretion of TGF-
ß1, which results in reduced bioavailability of extracellular
TGF-ß1. This leads to a lack of its tumor suppressive
effects in epithelial cells [8, 38].
LTBPs play a fundamental role as cellular chaperons for
latent TGF-ß [50]. It seems that the LTBPs have an indirect
tumor suppressive effect by supporting extracellular trans-
port of TGF-ß. It is not yet known whether there is an LTBP
receptor that would allow LTBPs to act via direct receptor
ligand interaction with the target cell [21]. A downregulation
of LTBP4 in neoplastic mammary epithelial cells in vitro, is
possibly indirectly correlated to the lack of the tumor
suppressive properties of TGF-ß1 [34]. The possible lack
of extracellular TGF-ß1 might play a role in the induction of
neoplastic transformation of mammary epithelial cells.
The data indicate that reduced LTBP4 expression might
possibly lead to reduced TGF-ß activity and possibly
reduced downstream signaling of TGF-ß.
Overall the results indicate a decrease in active TGF-ß1
signaling in neoplastic mammary tissue (DCIS and IDCs). A
decrease of TGF-ß1 signaling may result from decreased
synthesis, processing, or secretion of TGF-ß1. Therefore we
assayed conditioned media from cells which did not express
LTBP4 and monitored TGF-ß signaling by evaluating
SMAD-phosphorylation, an indicator of active TGF-ß signal-
ing. We found reduced SMAD signaling and partly modified
activation of downstream targets (data not shown).
This is in accordance with Yoshinaga et al., who generated
mice in which TGF-ß cannot bind to LTBP [62]. These mice
develop epithelial tumors which are associated with aberrant
TGF-ß signaling. Epithelial tumors due to disturbed TGF-ß
signaling are also observed in mouse models of smad3−/−
and APC delta 16, SMAD 4 +/−. In addition human colon
carcinomas are often associated with mutations of compo-
nents of the TGF-ß signaling pathway [3, 10, 14, 22, 58].
Previously it was assumed that TGF-ß acted directly on
the epithelial cells, and that the loss of TGF-ß signaling was
suppressed either in stromal cells or in T-cells [3]. But the
Fig. 3 RNA expression values of SMAD2 (a), SMAD3 (b) and
SMAD4 (c) in murine and human samples. Left panel: Expression in
WAP-TNP8 mice. Right panel: Expression in human mammary tissue.
Diagrams show the linearized raw expression values of the Affymetrix
Mouse Genome 430 2.0 GeneChip®/Affymetrix Human Genome
U133 Plus 2.0 GeneChip®. No changes in mRNA expression were
identified for SMAD2, SMAD3 and SMAD4. D: Immunoblot analysis
of p-SMAD expression after transfer of conditioned medium to
Hs578BsT or Hs578T cells or addition of recombinant TGF-ß1 (d1-5).
e Immunfluorescence of p-SMAD after incubation of Hs578BsT with
conditioned media of Hs578T (e1), incubation of Hs578BsT cells with
supernatant of Hs578BsT cells (e2), after incubation of Hs578T cells
with supernatant of Hs578BsT cells (e3). Red immunoreactivity shows
p-SMAD2/3 expression, blue staining is DAPI nucleic acid staining. f
Immunohistochemical staining of p-SMAD2/3 showing non-malignant
unchanged breast tissue with prominent p-SMAD expression (arrow)
(f1) and almost complete loss of immunoreactive p-SMAD signal in
mammary tumor tissue (F2) and total SMAD2/3 in non-malignant
breast tissue (arrow) (f3) and prominent total SMAD2/3 staining in
mammary tumor tissue
R
Fig. 4 Expression values of BMP4 in murine and human samples. a
Expression of BMP4 in WAP-TNP8 mice (left) and in human tissue
samples (right). Box and Whisker plots show the linearized raw
expression values of the Affymetrix Mouse Genome 430 2.0
GeneChip®/Affymetrix Human Genome U133 Plus 2.0. The expres-
sion of BMP4 is significantly reduced in the malignant tissues. b The
immunoblot shows a reduced expression of BMP4 in cell culture
tumor cells compared to non malignant cells and non-malignant
human mammary tissue. c Rescue of BMP4 expression and its
inhibitor gremlin in Hs578T cells to levels of non-malignant
mammary tissue by restoring TGF-ß1 activity via addition of
recombinant TGF-ß1
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mice also develop tumors in tissues that have normal TGF-
ß signaling, such as the stomach or intestine. Therefore, the
critical function of TGF-ß in the tumor microenvironment
may be rather to control tumor growth.
We found no inhibition of TGF-ß synthesis, but benign
human mammary cells contained significantly more active
TGF-ß as assayed by p-SMAD formation in vivo and in
vitro. Furthermore the results showed that BMP4, which
belongs to the TGF-ß superfamily, has been implicated in
the development and progression of malignant mammary
neoplasms. BMP4 directly promotes proliferation of breast
cancer cells [17, 24, 30, 56]. Our results demonstrated
reduced BMP4 (as well as reduced active TGF-ß) in DCIS
and IDCs which correlated with reduced active TGF-ß1.
Table 3 Down regulation of BMP4 in malignant tissues. p-values and Fold Changes of BMP4 in murine and human DCIS and IDC
Group p-value Fold change
Murine DCIS and IDC compared to non-malignant control 2 m 1,6E-01 1,1 ↓
3 m 2,6E-01 1,3 ↓
4 m 5,5E-02 1,1 ↓
5 m 3,5E-02 1,3 ↓
IDC 6,2E-03 2,9 ↓
Human DCIS and IDC compared to non-malignant control DCIS 3,4E-01 1,6 ↓
IDC 2,0E-02 1,6 ↓
p-values and Fold Changes of BMP4 in murine and human DCIS and IDC compared to non-malignant control samples (2 m=2 month after
lactation, 3 m=3 month after lactation, 4 m=4 month after lactation, 5 m=5 month after lactation, IDC = invasive ductal carcinoma). Fold
Changes were calculated using the median of the non-malignant controls compared to the different time points or the invasive tumors. Malignant
and premalignant tissues were down regulated compared to non-malignant controls. Microarray values are shown
Fig. 5 Expression values of
ID1 (a), ID2 (b) and GREM1
(c) in murine and human
samples. Left panel: Expression
in WAP-TNP8 mice, right
panel: Expression in human
mammary tissue. Diagrams
show the linearized raw
expression values of the
Affymetrix Mouse Genome 430
2.0 GeneChip®/Affymetrix
Human Genome U133 Plus 2.0
GeneChip®. Expression of ID1
is decreased in malignant tissues
in both murine and human
samples. Expression of ID2
and GREM1 is increased in
malignant tissues
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Aberrant expression of BMPs and changes in BMP4
signaling have been implicated in breast cancer. The
expression profiles of some BMPs in primary mammary
tumors differ significantly. Recent studies have provided
evidence that activation of BMP signaling may contribute
to aggressive behaviour of the cells. Gremlin, BMP4
antagonist and downstream target genes ID1 and ID2 have
been shown to prevent metastasis. Our results demonstrate
downregulation of BMP4 in neoplastic tissues compared to
non-malignant matched controls.
Decreased expression levels of BMP4 isoforms such as
BMP2, BMP4, BMP6 and BMP7 in breast carcinoma tissue
compared to tumor-free resection margins are frequently
found. These decreased BMP4 transcription levels are often
associated with bone metastasis [5], poor clinical outcome
and prognosis [4].
Although changes in the expression of specific BMPs
such as BMP4 in breast cancer are still the subject of
controversy, the aberrant expression of BMP4 has been
indicated in the development and progression of breast
cancer. The aberrations in the expression of BMP and
associated targets may be due to a modified activation of
TGF-ß, which in turn is possibly dependent on LTBP4
expression. Accordingly, gremlin as a BMP4 antagonist
was highly expressed in cancer cells [40] including breast
cancer. However the role of gremlin and other BMP
antagonists in breast cancer is far from clear.
Our microarray analysis revealed that BMP4 expression
was reduced in cancer cells in parallel with the increase of
expression of its inhibitor gremlin. Downregulation of the
BMP pathway was also reflected by the down-regulation of
the BMP4 target gene ID2. In addition, CTGF, which is a
direct target of both BMP4 and TGF-ß1 (data not shown),
was highly down-regulated in different epithelial cancer cells.
The addition of recombinant TGF-ß1 partially rescued the
BMP4 expression phenotype, further indicating the impor-
tance of this signaling cascade for the development of the
LTBP-4 −/− phenotype.
In summary these results indicate that reduced LTBP4
expression in mammary neoplasms modulates the bioavail-
Table 4 p-values and Fold Changes of ID1, ID2 and GREM1 in murine and human DCIS and IDC
Group p-value Fold change
ID1 Murine DCIS and IDC compared to non-malignant control 2 m 1,1E-01 1,83 ↓
3 m 8,6E-02 1,28 ↓
4 m 3,6E-02 1,81 ↓
5 m 1,3E-02 3,67 ↓
IDC 1,5E-02 3,14 ↓
Human DCIS and IDC compared to non-malignant control DCIS 4,5E-02 3,26 ↓
IDC 3,1E-02 8,66 ↓
ID2 Murine DCIS and IDC compared to non-malignant control 2 m 2,2E-02 2,13 ↑
3 m 3,1E-03 2,15 ↑
4 m 1,3E-02 2,13 ↑
5 m 1,6E-05 3,27 ↑
IDC 1,9E-04 3,21 ↑
Human DCIS and IDC compared to non-malignant control DCIS 6,2E-04 1,60 ↑
IDC 3,4E-02 2,36 ↑
GREM1 Murine DCIS and IDC compared to non-malignant control 2 m 1,1E-01 2,39 ↑
3 m 8,6E-02 1,10 ↑
4 m 3,6E-02 0,98 ↑
5 m 1,3E-02 0,91 ↑
IDC 1,5E-02 11,69 ↑
Human DCIS and IDC compared to non-malignant control DCIS 9,0E-03 6,03 ↑
IDC 4,7E-02 5,95 ↑
p-values and Fold Changes of ID1, ID2 and GREM1 in murine and human DCIS and IDC compared to non-malignant control samples (2 m=
2 month after lactation, 3 m=3 month after lactation, 4 m=4 month after lactation, 5 m=5 month after lactation, IDC = invasive ductal
carcinoma). Fold Changes were calculated using the median of the non-malignant controls compared to the different time points or the invasive
tumors. For ID1 Fold Changes represent lower expression compared to controls, for ID2 and GREM1 Fold Changes represent enhanced
expression in malignant tissues compared to non-malignant controls. Microarray values are shown.
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ability of TGF-ß as well as BMP4 expression with
modulation of the downstream signaling cascade, leading
to reduced SMAD signaling and reduced activation of
target genes. The results show that this modulation of TGF-
ß dependent target genes are a consequence of reduced
LTBP4 expression.
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